This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of cardiologic diseases. The acquisition was signed in June 2020 with one of Cheplapharm´s long standing partners. The APIs of the referring products are Colesevelam, Molsidomine, Acebutolol, Nadolol, Propranolol and Sotalol. The asset deal contains product registrations, intellectual property, certain contracts and inventory mainly valid for European Countries. The deal does not include any transfer of manufacturing facilites or employees.
“This investment underlines the value of our platform enabling us to further integrate products in our portfolio”, said CHEPLAPHARM´s CEO Sebastian F. Braun.